Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Becton Dickinson and Co (BDX) vs Medtronic PLC (MDT) Price & Performance

Becton Dickinson and CoTrade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Becton Dickinson and Co vs Medtronic PLC — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Medtronic PLC trades at $90.58 (market cap $114.45B). The key difference: Medtronic PLC is far larger — about 2.3× Becton Dickinson and Co's market cap, and Medtronic PLC pays the higher dividend (3.22%). Which is the better fit depends on your goals.

BDXMDT
Market Cap
$48.93B$114.45B
Sector
HealthHealth
52-Week High
$185.39$105.35
52-Week Low
$138.62$73.75
Enterprise Value
$65.03B$133.19B
Dividend Yield
2.34%3.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Becton Dickinson and Co

BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.

The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.

Medtronic PLC

Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.

The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT